Although the neurobiological basis of autism spectrum disorder (ASD) is not fully understood, recent studies have indicated the potential role of GABAA receptors in the pathophysiology of ASD. GABAA receptors play a crucial role in various neurodevelopmental processes and adult neuroplasticity. However, the mechanism(s) of regulation of GABAA receptors in ASD remains poorly understood.
Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. In vitro studies were performed in primary cortical neurons at days in vitro (DIV) 14. The protein levels were examined by western blotting. Immunofluorescence studies were employed for cellular localization. The gene expression was determined by RT-PCR array and qRT-PCR.
A significant decrease in GABAAα1 protein, but not mRNA levels was found in the middle frontal gyrus of ASD subjects indicating a post-translational regulation of GABAA receptors in ASD. At the cellular level, treatment with proteasomal inhibitor, MG132, or lactacystin significantly increased GABAAα1 protein levels and Lys48-linked polyubiquitination of GABAAα1, but reduced proteasome activity in mouse primary cortical neurons (DIV 14 from E16 embryos). Moreover, treatment with betulinic acid, a proteasome activator significantly decreased GABAAα1 protein levels in cortical neurons indicating the role of polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation in cortical neurons. Ubiquitination specific RT-PCR array followed by western blot analysis revealed a significant increase in SYVN1, an endoplasmic reticulum (ER)-associated degradation (ERAD) E3 ubiquitin ligase in the middle frontal gyrus of ASD subjects. In addition, the inhibition of proteasomal activity by MG132 increased the expression of GABAAα1 in the ER. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels in cortical neurons. Moreover, reduced association between SYVN1 and GABAAα1 was found in the middle frontal gyrus of ASD subjects.
SYVN1 plays a critical role as an E3 ligase in the ubiquitin proteasome system (UPS)-mediated GABAAα1 degradation. Thus, inhibition of the ubiquitin-proteasome-mediated GABAAα1 degradation may be an important mechanism for preventing GABAAα1 turnover to maintain GABAAα1 levels and GABA signaling in ASD.
Autism spectrum disorder (ASD) is among the most devastating neurodevelopmental disorders with a prevalence of about 1% of population worldwide. Although many theories have been suggested to explain the neurobiology of ASD, the exact mechanism is still not understood. Recent studies indicate the role of the inhibitory neuronal circuit dysfunction in the pathophysiology of ASD . γ-amino butyric acid (GABA) is the major inhibitory neurotransmitter in the brain, and studies have shown an association between ASD and GABAergic system . GABAA receptors mediate the fast inhibitory neurotransmission within the CNS, and most GABAA receptors are composed of 2α, 2β, and 1γ or δ-subunit . GABAAα1 is expressed ubiquitously in the brain  and is present over 60% of cortical GABAA receptors . It is considered to be responsible for sedative effects of positive allosteric modulators of the GABAA system, such as diazepam . Since GABAAα1 is the major receptor in the GABA system, its dysfunction significantly affects GABA signaling and therefore, brain physiology [7–10]. A significant reduction in GABAAα1 protein levels has been found in the frontal cortex of ASD subjects . However, the mechanism(s) of GABAAα1 regulation in ASD is still not clear.
The ubiquitin-proteasome system (UPS) is a major non-lysosomal proteolytic process that regulates the levels of cellular proteins including those involved in neuronal growth and function . Moreover, UPS has been shown to regulate a number of GABA receptors suggesting a possible relationship between UPS and GABAergic system [13–15]. The UPS consists of concerted actions of three classes of enzymes that link the polypeptide co-factor, ubiquitin (Ub) onto proteins to mark them for degradation [16, 17]. In the first step, the C-terminus of Ub forms a thioester bond with the catalytic cysteine of an E1 Ub-activating enzyme. In the second step, Ub is transferred from the E1 to the catalytic cysteine of the E2, Ub-conjugating enzyme. Finally, the E2 - Ub conjugate cooperates with an E3 (ligase) to transfer Ub to the substrate. Moreover, the interaction between an E3 ligase and its target molecule is a key step in determining the selectivity of UPS for a target molecule and its proteasomal degradation.
The present study investigated the role of ubiquitination in the regulation of GABAAα1 in ASD. We have examined the hypothesis that GABAAα1 protein levels are degraded through a UPS-mediated pathway in ASD. We tested the above hypothesis in postmortem middle frontal gyrus samples from ASD and control subjects. The middle frontal gyrus contains the core portion of dorsolateral prefrontal cortex, a region primarily associated with cognition and executive functions. A large body of evidence including reports from neurocognitive as well as neuroimaging studies has implicated middle frontal gyrus in the pathophysiology of ASD [18–20].
The Georgia Regents University (GRU) Institutional Review Board has deemed this study exempt from the full review due to the use of de-identified human postmortem brain samples, with no possibility to track back the identity of the donors. Animal use procedures were performed after being reviewed and approved by GRU, Committee on Animal Use for Research (protocol# 2010-0056). Procedures were consistent with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines as per Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Postmortem brain tissues from middle frontal gyrus of ASD (N = 13) and control (N = 13) subjects were received from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD, USA. Detailed description on the demographics of samples is given in Additional file 1: Table S1. None of the controls had any known history of neuropsychiatric disorders or illicit drug use. 9 out of 13 subjects with ASD had information on Autism Diagnostic Interview-Revised (ADI-R). Confounding variables such as PMI, refrigeration interval, age at death, RNA integrity, and brain pH did not show any significant difference between ASD and control subjects (Table 1). The brain samples were shipped frozen and stored at -80°C until analysis. Brain tissue was homogenized in a tissue lysis buffer containing 50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 150 mM NaCl, 1.0% Triton X-100, 1.0% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 6 μM PMSF, and protease inhibitor cocktail (Sigma) followed by centrifugation at 13,000 rpm for 10 min at 4°C. The supernatant was used for protein estimation by the bicinchoninic acid method (BCA Protein Assay Kit, Thermo).
Primary cortical neurons
Timed pregnant CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Cerebral cortical neurons were prepared as described previously . Briefly, cerebral cortices from embryos at E16 were aseptically dissected and plated at 3.5 × 105 cells per well on polyethyleneimine-coated 6-well plates. Neurons were cultured in Neurobasal medium supplemented with 2 mM L-glutamine, B27 and antibiotics (Invitrogen). The media was replaced with Neurobasal supplemented with B27 minus antioxidants, glutamine, and antibiotics on the third day in vitro (DIV 3). Treatment of neurons was conducted at DIV 14. The following pharmacological treatments were used: MG132 (20 μM); lactacystin (50 μM); or betulinic acid (20 μg/mL) (all the reagents were from Tocris Biosciences, Minneapolis, MN, USA). At the end of the treatments, cells were washed in Phosphate Buffered Saline (PBS) and lysed in ice-cold lysis buffer supplemented with protease inhibitor cocktail (Sigma) for immunoblotting.
Protein samples (30 to 40 μg) were subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was then blocked for 1 h in PBS with the detergent Tween 20 and 5% non-fat milk or 5% BSA followed by overnight incubation with a primary antibody. The primary antibodies used were: anti-GABAAα1 (1:1,000, PhosphoSolutions, Aurora, CO, USA); anti-GABAAγ2 (1:200; Santa Cruz Biotechnology); anti-GABAAα2 (1:200; Santa Cruz Biotechnology); anti-GABAAα3 (1:200; Santa Cruz Biotechnology); anti-SYVN1 (1:1,000, Sigma) or anti- ubiquitin Lys48-specific (clone Apu2, 1:1,000, Millipore). Following washing, the membranes were incubated with secondary antibody for 1 h. We used enhanced chemiluminescence detection reagent kit (Thermo Scientific) to detect the proteins. The intensity of the bands was quantified using densitometry software (Image J, NIH). The immunoblot data was corrected for corresponding GAPDH (1:5,000, Cell Signaling) values. Immunoprecipitation was performed using the Crosslink Immunoprecipitation Kit (Pierce, cat# 26147). Briefly, precipitating antibody (10 μg) was bound to protein A/G plus agarose for 1 h followed by cross linking using disuccinimidyl suberate (DDS) crosslinker. The antibody-crosslinked resin was incubated overnight with the pre-cleared lysate (200 μg). Lysate preclearance was carried out using control agarose resin for 1 h. Antigen co-precipitated with antibody-crosslinked resin was eluted and subjected for SDS-PAGE analysis as described above.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from postmortem brain tissues using a commercially available kit (SV RNA Isolation, Promega, Madison, WI, USA). qRT-PCR was performed on a MasterCycler (Eppendorf) using a SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA, USA). A typical reaction of a total volume of 25 μL consisted of 0.5 μL Superscript III RT/Platinum Taq mix, 12.5 μL 2X SYBR Green Reaction Mix (includes 0.4 mM of each dNTP and 6 mM MgSO4), 12.5 pMol of each of forward or reverse primers, and 4 μL DEPC-treated water, and 3ul of purified RNA. PCR amplification was done with an initial incubation at 55°C for 1,200 s, then at 95°C for 120 s followed by 35 cycles of 95°C for 15 s, 50°C for 30 s, 72°C for 30 s, and final melting curve from 55°C to 95°C with 0.2 C/s. Primer specificity was confirmed by melting curve analysis and electrophoresis of PCR products on a 2% agarose gel to confirm the presence of a single band of the predicted size. The mRNA for GABAAα1 and SYVN1 were normalized to two control genes (glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and ß-actin) and a geometric mean of these genes. Primers utilized were as follows: GABAAα1 (forward, 5’-GGATTGGGAGAGCGTGTAACC and reverse, 5’- TGAAACGGGTCCGAAACTG), SYVN1 (forward, 5’-GTTTACAGGCTTCATCAAGG and reverse, 5’-CATGATGGCATCTGTCACAG), GAPDH (forward,5’-GAGTCAACGGATTTGGTCGT-3’ and reverse, 5’-TTGATTTTGGAGGGATCTCG-3’), and ß-actin (forward, 5’-GGACTTCGAGCAAGAGATGG–3’ and reverse, 5’-AGCACTGTGTTGGCGTACAG-3’).
Small interfering RNA (siRNA)
The control as well as SYVN1 siRNA were purchased from Dharmacon Research Inc. Transfection of both siRNAs (50 nM) was performed using Effectene Transfection Reagent (Qiagen). Lysates were collected at 48 h after the transfection.
Human Ubiquitination Pathway PCR Array
The human Ubiquitination Pathway RT2 Profiler PCR Array (SA Biosciences, Qiagen, Valencia, CA, USA) was used to determine the profile of genes involved in UPS pathway as per the manufacturer’s instructions. The array determines the gene expression of 84 molecules in the family of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). The integrated web-based software package was used for data analysis (http://www.SABiosciences.com/pcrarraydataanalysis.php).
Proteasome activity assay
The proteasome activity was measured using the 20S proteasome activity assay kit (Millipore) according to the manufacturer’s instructions. Primary cortical neurons (DIV 14) were treated with vehicle (DMSO), MG132 (20 μM), or lactacystin (50 μM) for 9 h. Cells were washed with PBS and lysed in cell lysis buffer (50 mm Tris, pH 7.4, 2 mm dithiothreitol, 5 mm MgCl2, 2 mm ATP). Following homogenization and centrifugation, 100 μg of protein of each sample was diluted to a final volume of 100 μL with assay buffer (250 mM HEPES, pH 7.5, 5 mM EDTA, 0.5% NP-40, and 0.01% SDS) and proteasome substrate, SucLLVY-7-amido-4-methylcoumarin. The assay was based on detection of the fluorophore 7-amino-4-methylcoumarin (AMC) after cleavage from the labeled substrate. The free AMC fluorescence was quantified using a Synergy HT Multi-detection Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at 380/460 nm and 37°C.
Primary cortical neurons (DIV 14) were treated with vehicle (DMSO) or MG132 (20 μM) for 9 h. Cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. After washing with PBS, the cells were blocked with 10% goat serum in 0.2% Triton X-100/PBS for 2 h at 37°C and incubated with rabbit anti- GABAAα1 (1:200) and mouse anti-PDI (1:1,000; Enzo Life Sciences, Farmingdale, NY, USA) overnight at 4°C. After washing and incubation with Cy3 or Cy2-based secondary antibodies (1:200), the cells were washed extensively with PBS, and mounted with ProLong Gold Antifade Reagent with DAPI (Invitrogen). Confocal images were taken with a Zeiss LSM-510 confocal microscope. Colocalization of proteins was confirmed by z stack analysis. Data show representative single plane images.
One-way ANOVA with Bonferroni’s multiple comparison test for post-hoc analysis or Student’s t test was used in cell culture studies. In postmortem data analysis, univariate general linear models were used to examine the differences in mRNA and protein expression levels between subjects with ASD and the controls (that is, affection status). To examine the unique effects of affection status on mRNA and protein expression, age, postmortem interval, storage time, sample pH, and/or RNA integrity number were evaluated and added to the model as potential covariates. The small sample size used to conduct the Analysis of Covariance (ANCOVA) implied a decreased power to detect effects. In order to maximize the observed power, only covariates that had at least small-to-moderate associations with the dependent variable were included in the model. Candidate covariates that were significantly correlated with mRNA or protein expression were included in the model. Partial eta-squared coefficients were computed as estimates of effect size. Exact probability (P) values of less than 5% were considered significant. Depending on distributional characteristics of the data, simple or non-parametric correlations were computed to examine the association of covariates and clinical variables with mRNA and protein expression levels. Pearson’s product moment correlation was used for the correlation analysis. All analyses were performed using SPSS Statistics 20 software (IBM).
Decrease in GABAAα1 protein, but not mRNA levels in the middle frontal gyrus of ASD subjects
Since the postmortem findings can be significantly affected by confounding variables such as age, sex, postmortem interval (PMI), pH, and RNA integrity number (RIN), all statistical analysis was adjusted for these covariates. For each protein (or gene) expression level, insignificant covariates were removed and then a statistical model was established to correct for any significant covariates. Additional file 2: Table S2 summarizes the distributional characteristics of study variables. For each molecule, candidate covariates included in the model had a correlation magnitude of 0.10 and above.
Expression of GABAAα1 was examined in the middle frontal gyrus of ASD and control subjects by western blotting (Figure 1A). Including sample pH as a covariate in the model, the predicted main effect of affection status was statistically significant (F(1, 21) = 4.57, P = 0.045, η2p = 0.179). In contrast, the main effect of sample pH was not statistically significant (F(1, 21) = 0.19, P = 0.89, η2p = 0.001). Subjects with ASD demonstrated lower levels of GABAAα1 protein expression (EMM (estimated marginal means) = 0.649, SE (standard error) = 0.113) than controls (EMM = 0.997, SE = 0.113). However, we did not find any significant change in the protein levels of GABAAα2, GABAAα3, and GABAAγ2 in ASD subjects as compared to controls (Figure 1B to D). To determine whether GABAAα1 downregulation occurred at the mRNA level, we examined the GABAAα1 mRNA expression in the middle frontal gyrus of ASD and control subjects (Figure 1E). An ANCOVA (between-subjects factor: affection status (ASD, control); covariates: age, storage interval, RNA integrity number) demonstrated no main effect of affection status, F(1, 19) = 0.056, P = 0.82, η2p = 0.003. The main effects of age (F(1, 19) = 4.26, P = 0.053, η2p = 0.183), storage interval (F(1, 19) = 2.61, P = 0.123, η2p = 0.12), and RNA integrity number (F(1, 19) = 1.25, P = 0.277, η2p = 0.062) were not statistically significant. No significant correlation was found between the mRNA or protein expression of GABAAα1 and the confounding variables, such as age at death, PMI, refrigeration interval, brain pH, or RNA integrity (Table 2). In addition, we did not observe any association between the ASD diagnostic scores and GABAAα1 mRNA or protein in ASD subjects. These results indicate that GABAAα1 levels are lower in the middle frontal gyrus of ASD subjects, which occurred at the post-translational level.
GABAAα1 levels are regulated through ubiquitin-proteasomal degradation
It is known that proteasome-mediated degradation of cellular proteins including molecules involved in neuroplasticity is a critical mechanism for the post-translational regulation of protein turnover . Given that the GABAAα1 downregulation in the ASD subjects occurred at the post-translational level, we examined whether proteasomal degradation would play a major role in this process. To examine whether GABAAα1s are degraded by proteasomes, we treated cultured primary cortical neurons for 9 h with the proteasomal inhibitors, lactacystin or MG132, and determined proteasome activity and GABAAα1 protein levels. We found significant reductions in proteasome activity following treatment with MG132 and lactacystin in neurons (Figure 2A). In addition, both MG132 (Figure 2B) and lactacystin (Figure 2C) significantly increased GABAAα1 protein levels as compared to vehicle-treated neurons. Next, we examined whether increasing proteasome activity could decrease GABAAα1 protein levels in neurons. We treated cultured primary cortical neurons for 9 h with a proteasome activator, betulinic acid, and determined the GABAAα1 protein levels. The treatment with betulinic acid significantly decreased GABAAα1 protein levels in cortical neurons (Figure 2D). These findings suggest that proteasomal degradation plays an important role in the regulation of GABAAα1 receptors in neurons.
An important step in the proteasomal degradation pathway is the formation of an ubiquitin-protein conjugate . The ubiquitination leads to the covalent binding of ubiquitin ligase to the target molecule and subsequent degradation of the molecule by the 26 S proteasome . Specifically, Lys-48 linked poly-ubiquitination is most commonly associated with proteins targeted for proteasomal degradation . We found an interaction between GABAAα1 and Lys48-ubiquitin in cortical neurons suggesting a possible Lys48-linked polyubiquitination of GABAAα1 in neurons (Figure 2E). Moreover, treatment with MG132 significantly increased Lys48-linked polyubiquitination of GABAAα1 in neurons as determined by immunoprecipitation. Collectively, the preventive effect of proteasome inhibitors on GABAAα1 degradation, increased proteasome activity, and Lys48-linked polyubiquitination of GABAAα1 indicate that polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation occurs in cortical neurons.
Ubiquitination pathway is altered in the middle frontal gyrus of ASD subjects
Since we found a potential role of ubiquitination-mediated proteasomal pathway in GABAAα1 regulation, we examined the ubiquitination profile in the postmortem samples from ASD and control subjects using ubiquitination-specific RT-PCR array. The array consisted of 84 genes belonging to E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) family. The data were analyzed to the arithmetic mean of three housekeeping genes (HPRT1, RPL13A, and GAPDH). Additional file 3: Table S3 summarizes the fold change and P values for the ubiquitin ligases examined in ASD and control subjects. The cutoff fold change for significance in the array was set to ≥2 as per the assay instructions. Accordingly, SYVN1 was the only E3 ligase which showed statistically significant fold difference between ASD and control subjects in the array. The data on SYVN1 from the array were further confirmed using western blot analysis (Figure 3). There was a statistically significant difference between people with ASD (EMM = 1.30, SE = 0.17) and controls (EMM = 0.766, SE = 0.17) in their SYVN1 protein expression with greater increase in SYVN1 in the ASD group (F(1, 21) = 4.561, P = 0.044, η2p = 0.172). Age, postmortem interval, and RNA integrity number were all included in the model as covariates. Age (F(1, 21) = 10.73, P = 0.003, η2p = 0.328) and RNA integrity number (F(1, 21) = 6.45, P = 0.019, η2p = 0.23) were the only significant covariates in the model. The above data indicate that the alterations in the expression of SYVN1 occur at both mRNA and protein levels. We did not find any significant correlation between the protein expression of SYVN1 and the confounding variables, such as age at death, PMI, refrigeration interval, brain pH, or RNA integrity in control or ASD subjects (Table 3). However, a large and statistically significant inverse correlation (r = -0.712; P = 0.047) was observed between SYVN1 levels and non-verbal communication.
SYVN1 is the E3 ligase associated with GABAAα1
We sought to examine whether SYVN1 is the E3 ligase partner of GABAAα1 responsible for the GABAAα1 ubiquitination and its proteasomal degradation. We performed immunoprecipitation assay to determine possible GABAAα1 conjugation with SYVN1 in mouse primary cortical neurons, and each of these immunoprecipitates was examined for co-purification of SYVN1 by western blot. SYVN1 was detected in GABAAα1 immunoprecipitates, but not in the control IgG (Figure 4A). The above interaction was further confirmed using a reciprocal approach, where GABAAα1 co-purified with SYVN1, but not with a control IgG. Since SYVN1 is a known ER-associated degradation (ERAD) E3 ubiquitin ligase, we next examined whether inhibiting the proteasomal activity would lead to the accumulation of GABAAα1 in ER. MG132 significantly increased the expression of GABAAα1 in the ER as evidenced by the increase in the complex between GABAAα1 and ER marker, PDI (Figure 4B).
Next, we examined the causal relationship between SYVN1 and GABAAα1 degradation by using SYVN1 siRNA in neurons. Primary cortical neurons were treated with siCONTROL or the SYVN1 siRNA, and the expression of SYVN1 and GABAAα1 protein levels were determined. The SYVN1 expression level was significantly reduced in those cells transfected with the SYVN1 siRNA when examined 48 h after the transfection. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels, as compared with the siCONTROL transfectants (P <0.05; Figure 4C). We performed immunoprecipitation assay to determine whether the association between GABAAα1 and SYVN1 is altered in ASD. We found a reduced interaction between GABAAα1 and SYVN1 in the middle frontal gyrus of ASD subjects as compared to controls (Figure 4D). Taken together, these results indicate that SYVN1 plays a critical role as an E3 ligase in the UPS-mediated GABAAα1 degradation.
The findings from the present study demonstrate a UPS-mediated mechanism critical for the post-translational regulation of the GABAAα1. In primary cortical neurons, the UPS-mediated GABAAα1 degradation contributed to the physiological GABAAα1 turnover because inhibition of the proteasome activity improved the basal level of endogenous GABAAα1 levels. The UPS-mediated GABAAα1 turnover was also substantially enhanced in the cortical samples from ASD subjects resulting in altered GABAAα1 levels. Because the GABAergic system plays an important role in a variety of cellular functions including neuroplasticity, preventing an excessive GABAAα1 turnover may be an important mechanism in maintaining GABAAα1 levels and GABA signaling.
Our data show that the change in GABAAα1 expression in ASD occurs at the post-translational level. Although an earlier study has reported decrease in GABAAα1 protein levels in the frontal cortex of autism , the receptor status at the mRNA level has never been examined before. Given that UPS plays an important role in the regulation of receptors, we examined the role of UPS activity in the downregulation of GABAAα1 using postmortem brain samples as well as mouse primary cortical neurons. Our data demonstrate that the expression of SYVN1 was higher in the tissue samples from ASD as compared to controls. Moreover, treatment with proteasomal inhibitors as well as inhibition of E3 ubiquitin ligase (SYVN1) significantly increased GABAAα1 protein levels in cortical neurons. These results indicate that the degradation of GABAAα1 may be subject to proteasomal regulation through a SYVN1-mediated cellular pathway.
GABAA receptors play important roles in various neurodevelopmental processes including proliferation, migration, and differentiation of precursor cells [7–10]. The α1 subunit receptors appear to be responsible for sedative effects of positive allosteric modulators of the GABAA system, such as diazepam . Moreover, reductions in GABAA receptor binding have been found in the hippocampus  and anterior and posterior cingulate cortex [25, 26] of ASD subjects. The above changes in receptor densities/affinities have also been reflected in receptor expression levels. GABAAα1 protein levels were significantly lower in the superior frontal cortex and parietal cortex of subjects with autism . However, the mechanisms of regulation of GABAAα1 in ASD were not clearly understood. GABAA receptor subunits are inserted co-translationally into the membrane of the ER and oligomerized in the presence of ER-resident chaperones. The ERAD plays an important role in the degradation of un- or misfolded GABA receptors [27, 28]. Accordingly, a recent study has indicated that even relatively low levels of ER stress may alter the membrane trafficking of the synaptic functional molecules such as GABA receptors leading to ASD pathophysiology . It has been shown that the ubiquitination of GABAAα1 targets the unassembled subunits within the ER for proteasome-dependent degradation . The increase in GABAAα1 protein levels following proteasomal inhibition in the present study supports the above findings. Moreover, we identified the SYVN1 as the ERAD E3 ubiquitin ligase involved in GABAAα1 regulation using in vitro neurons. Interestingly, SYVN1 has recently been reported in the regulation of GABAB receptors  suggesting that ERAD plays an important role in the control of functional GABA receptors and their trafficking.
The findings from the present study may have functional implications in the cellular mechanisms of ASD pathophysiology. Recent studies have shed light on the neurobiology of ASD including those related to the GABAergic system  and ER stress . The present data suggest a possible link between regulation of GABAAα1 turnover and the ERAD-mediated proteasomal degradation pathway. The above relationship should be further investigated in vivo using an appropriate animal model for autism such as fragile-X knockout or BTBR mouse. In addition, the current findings represent only one brain region whereas abnormalities in GABAergic function have been reported in many other brain regions including hippocampus in ASD. Therefore, additional studies should investigate the role of proteasomal degradation pathway in GABAAα1 regulation in other brain regions implicated in ASD. The present data may have potential clinical implications. For example, using proteasome inhibitor and/or targeting key elements of the UPS-mediated GABAAα1 turnover (for example, SYVN1) could offer a new strategy for treating GABAergic deficits often seen in ASD and related CNS disorders.
Availability of supporting data
The datasets supporting the results of this article are included within the article and its additional files.
Autism diagnostic interview revised
Autism spectrum disorders
Endoplasmic-reticulum-associated protein degradation GABA, γ-amino butyric acid
Synovial apoptosis inhibitor 1
Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ: GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev. 2012, 36: 2044-2055. 10.1016/j.neubiorev.2012.07.005.
Rossignol E: Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders. Neural Plast. 2011, 2011: 649325.
Möhler H: GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006, 326: 505-516. 10.1007/s00441-006-0284-3.
Wisden W, Laurie DJ, Monyer H, Seeburg PH: The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci. 1992, 12: 1040-1062.
Beneyto M, Abbott A, Hashimoto T, Lewis DA: Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb Cortex. 2011, 21: 999-1011. 10.1093/cercor/bhq169.
Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Mohler H: Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999, 401: 796-800. 10.1038/44579.
Barker JL, Behar T, Li YX, Liu QY, Ma W, Maric D, Maric I, Schaffner AE, Serafini R, Smith SV, Somogyi R, Vautrin JY, Wen XL, Xian H: GABAergic cells and signals in CNS development. Perspect Dev Neurobiol. 1998, 5: 305-322.
Conti F, Minelli A, Melone M: GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res Brain Res Rev. 2004, 45: 196-212. 10.1016/j.brainresrev.2004.03.003.
Akerman CJ, Cline HT: Refining the roles of GABAergic signaling during neural circuit formation. Trends Neurosci. 2007, 30: 382-389. 10.1016/j.tins.2007.06.002.
Di Cristo G: Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders. Clin Genet. 2007, 72: 1-8. 10.1111/j.1399-0004.2007.00822.x.
Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD: GABA(A) receptor downregulation in brains of subjects with autism. J Autism Dev Disord. 2009, 39: 223-230. 10.1007/s10803-008-0646-7.
Jarome TJ, Helmstetter FJ: The ubiquitin-proteasome system as a critical regulator of synaptic plasticity and long-term memory formation. Neurobiol Learn Mem. 2013, 105: 107-116.
Arancibia-Cárcamo IL, Yuen EY, Muir J, Lumb MJ, Michels G, Saliba RS, Smart TG, Yan Z, Kittler JT, Moss SJ: Ubiquitin-dependent lysosomal targeting of GABA(A) receptors regulates neuronal inhibition. Proc Natl Acad Sci U S A. 2009, 106: 17552-17557. 10.1073/pnas.0905502106.
Zemoura K, Schenkel M, Acuña MA, Yévenes GE, Zeilhofer HU, Benke D: Endoplasmic reticulum-associated degradation controls cell surface expression of γ-aminobutyric acid, type B receptors. J Biol Chem. 2013, 288: 34897-34905. 10.1074/jbc.M113.514745.
Zemoura K, Benke D: Proteasomal degradation of γ-Aminobutyric AcidB receptors is mediated by the interaction of the GABAB2 C terminus with the proteasomal ATPase Rtp6 and regulated by Neuronal Activity. J Biol Chem. 2014, 289: 7738-7746. 10.1074/jbc.M113.541987.
Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002, 82: 373-428.
Pickart CM: Back to the future with ubiquitin. Cell. 2004, 116: 181-190. 10.1016/S0092-8674(03)01074-2.
Carper RA, Courchesne E: Localized enlargement of the frontal cortex in early autism. Biol Psychiatry. 2005, 57: 126-133. 10.1016/j.biopsych.2004.11.005.
Barendse EM, Hendriks MP, Jansen JF, Backes WH, Hofman PA, Thoonen G, Kessels RP, Aldenkamp AP: Working memory deficits in high-functioning adolescents with autism spectrum disorders: neuropsychological and neuroimaging correlates. J Neurodev Disord. 2013, 5: 14-10.1186/1866-1955-5-14.
Zikopoulos B, Barbas H: Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neurosci. 2013, 7: 609.
Howell KR, Hoda MN, Pillai A: VEGF activates NR2B phosphorylation through Dab1 pathway. Neurosci Lett. 2013, 552: 30-34.
Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem. 1998, 67: 425-479. 10.1146/annurev.biochem.67.1.425.
Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM: Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001, 61: 4985-4989.
Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML: Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord. 2001, 31: 537-543. 10.1023/A:1013238809666.
Oblak A, Gibbs TT, Blatt GJ: Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Res. 2009, 2: 205-219. 10.1002/aur.88.
Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011, 1380: 218-228.
Kang JQ, Macdonald RL: The GABAA receptor gamma2 subunit R43Q mutation linked to childhood absence epilepsy and febrile seizures causes retention of alpha1beta2gamma2S receptors in the endoplasmic reticulum. J Neurosci. 2004, 24: 8672-8677. 10.1523/JNEUROSCI.2717-04.2004.
Gallagher MJ, Shen W, Song L, Macdonald RL: Endoplasmic reticulum retention and associated degradation of a GABAA receptor epilepsy mutation that inserts an aspartate in the M3 transmembrane segment of the alpha1 subunit. J Biol Chem. 2005, 280: 37995-38004. 10.1074/jbc.M508305200.
Fujita E, Dai H, Tanabe Y, Zhiling Y, Yamagata T, Miyakawa T, Tanokura M, Momoi MY, Momoi T: Autism spectrum disorder is related to endoplasmic reticulum stress induced by mutations in the synaptic cell adhesion molecule, CADM1. Cell Death Dis. 2010, 1: e47-10.1038/cddis.2010.23.
Human postmortem samples were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD, USA. The Bank is funded by NIH Contract No. #HHSN275200900011C, Ref. No. NO1-HD-9-0011.
The authors declare that they have no competing interests.
AC carried out the gene as well as protein expression studies, and drafted the manuscript. CDP and DP performed the immunoprecipitation and immunofluorescence studies, and helped to draft the manuscript. AOA carried out the statistical analysis and helped to revise the manuscript. AP conceived of the study, and participated in its design and coordination and wrote the manuscript. All authors read and approved the final manuscript.
Amanda Crider, Chirayu D Pandya contributed equally to this work.
About this article
Cite this article
Crider, A., Pandya, C.D., Peter, D. et al. Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder. Molecular Autism 5, 45 (2014). https://doi.org/10.1186/2040-2392-5-45
- GABAA receptor